Text Size

Anakinra as a Treatment for Hydradenitis Suppurativa

This study is currently recruiting participants.
Verified October 2012 by University of California, San Francisco
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01516749
First received: December 7, 2011
Last updated: October 12, 2012
Last verified: October 2012
History of Changes
  Purpose

This is an open-label, proof-of-concept research study to assess the effectiveness of anakinra in the treatment of patients with hidradenitis suppurativa (HS). The planned intervention is to provide about 6 HS patients with anakinra 100mg daily injections to administer subcutaneously for 8 weeks. Then, the study subjects will be followed for a further 8 weeks to monitor for relapse of HS.


Condition Intervention Phase
Hidradenitis Suppurativa
 Drug: anakinra
 Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa

Resource links provided by NLM:

Drug Information available for: Anakinra
U.S. FDA Resources

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Modified sartorius score [ Time Frame: Difference in disease severity from baseline will be assessed at the following timepoints: 0, 2, 4, 8, 12, & 16 weeks ] [ Designated as safety issue: No ]
    To assess the efficacy of anakinra in the treatment of HS as shown by reduction in objective measures (Modified Sartorius Score) and subjective measures (physician and patient global assessment of pain, odor, and discharge).


Secondary Outcome Measures:
  • Quality of life assessments [ Time Frame: Difference in quality of life from baseline will be measured at the following timepoints: 0, 2, 4, 8, 12, & 16 weeks ] [ Designated as safety issue: No ]
    To assess changes in health-related quality of life as shown by subjective quality of life indices such as the Dermatology Life Quality Index (DLQI) and the Short Form 36 (SF-36). Also, to assess tolerability of anakinra as a treatment for HS.


Estimated Enrollment: 6
Study Start Date: October 2012
Estimated Study Completion Date: October 2014
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Anakinra
All patients in this arm will receive the investigation drug anakinra once daily subcutaneously.
 Drug: anakinra
Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
Other Name: Kineret[TM]

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1) Signed informed consent form with Confirmed diagnosis of hidradenitis suppurativa with moderate or severe disease activity

Exclusion Criteria:

  1. Use of the following therapies:

    • Etanercept in the 4 weeks prior to the baseline visit (Day 1)
    • Adalimumab in the 8 weeks prior to the baseline visit (Day 1)
    • Infliximab in the 12 weeks prior to the baseline visit (Day 1)
    • Any other investigational biologics in the 8 weeks prior to the baseline visit (Day 1)
    • Leflunomide in the 4 weeks prior to the baseline visit (Day 1) • Thalidomide in the 4 weeks prior to the baseline visit (Day 1)
    • Cyclosporine in the 4 weeks prior to the baseline visit (Day 1)
    • I.V. immunoglobulin (I.V. Ig) in the 8 weeks prior to the baseline visit (Day 1)
    • 6-Mercaptopurine, azathioprine, cyclophosphamide, or chlorambucil in the 12 weeks prior to the baseline visit (Day 1)
    • Colchicine, dapsone, mycophenolate mofetil & systemic antibiotics in the 3 weeks prior to the baseline visit (Day 1)
    • Corticosteroids "20mg/day or >0.4 mg/kg, whichever applies, in the 1 week prior to the baseline visit (Day 1)
  2. history of immunocompromise including HIV infection
  3. positive Hep B surface antigen -
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01516749

Contacts
Contact: Kieron S Leslie, M.D. 4152068660 lesliek@derm.ucsf.edu
Contact: Tien V Nguyen, B.A. 9727439685 letien62nguyen@gmail.com

Locations
United States, California
San Francisco General Hospital Recruiting
San Francisco, California, United States, 94110
Principal Investigator: Kieron S Leslie, MD            
Sub-Investigator: Tien V Nguyen, BA            
Sub-Investigator: Toby Maurer, MD            
Sub-Investigator: Erin Amerson, MD            
Sub-Investigator: Maribel Amodo, RN            
Sub-Investigator: Mike Rosenblum, MD, PhD            
Sub-Investigator: Shivani Tripathy, MD            
Sponsors and Collaborators
University of California, San Francisco
Investigators
Principal Investigator: Kieron S Leslie, M.D. University of California, San Francisco - Department of Dermatology
  More Information

Publications:

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01516749     History of Changes
Other Study ID Numbers: 11-08101
Study First Received: December 7, 2011
Last Updated: October 12, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by University of California, San Francisco:
hidradenitis suppurativa
anakinra

Additional relevant MeSH terms:
Hidradenitis Suppurativa
Hidradenitis
Sweat Gland Diseases
Skin Diseases
Skin Diseases, Bacterial
Bacterial Infections
Skin Diseases, Infectious
 Infection
Suppuration
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2013